{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-10-02",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "product_ndc": "0517-2901",
      "marketing_end_date": "20270930",
      "generic_name": "glucagon injection",
      "labeler_name": "American Regent, Inc.",
      "brand_name": "Gvoke VialDx",
      "active_ingredients": [
        {
          "name": "GLUCAGON",
          "strength": "1 mg/.2mL"
        }
      ],
      "finished": true,
      "packaging": [
        {
          "package_ndc": "0517-2901-01",
          "description": "1 VIAL in 1 CARTON (0517-2901-01)  / .2 mL in 1 VIAL",
          "marketing_start_date": "20250819",
          "marketing_end_date": "20270930",
          "sample": false
        },
        {
          "package_ndc": "0517-2901-10",
          "description": "10 VIAL in 1 CARTON (0517-2901-10)  / .2 mL in 1 VIAL",
          "marketing_start_date": "20250819",
          "marketing_end_date": "20270930",
          "sample": false
        }
      ],
      "openfda": {
        "manufacturer_name": [
          "American Regent, Inc."
        ],
        "rxcui": [
          "2587358",
          "2587361"
        ],
        "spl_set_id": [
          "359982a8-ec5c-4927-8c0f-89771e0f942b"
        ],
        "is_original_packager": [
          true
        ],
        "nui": [
          "N0000190852",
          "N0000190853",
          "N0000009340",
          "N0000009345",
          "N0000008636",
          "N0000008635",
          "N0000008652"
        ],
        "pharm_class_epc": [
          "Antihypoglycemic Agent [EPC]",
          "Gastrointestinal Motility Inhibitor [EPC]"
        ],
        "pharm_class_pe": [
          "Increased Gluconeogenesis [PE]",
          "Increased Glycogenolysis [PE]",
          "Decreased GI Smooth Muscle Tone [PE]",
          "Decreased GI Motility [PE]",
          "Decreased Glycolysis [PE]"
        ],
        "unii": [
          "76LA80IG2G"
        ]
      },
      "marketing_category": "NDA",
      "dosage_form": "INJECTION, SOLUTION",
      "spl_id": "054da60f-7e40-4886-912a-1034c09be68b",
      "product_type": "HUMAN PRESCRIPTION DRUG",
      "route": [
        "INTRAVENOUS"
      ],
      "marketing_start_date": "20250819",
      "product_id": "0517-2901_054da60f-7e40-4886-912a-1034c09be68b",
      "application_number": "NDA212097",
      "brand_name_base": "Gvoke VialDx",
      "pharm_class": [
        "Antihypoglycemic Agent [EPC]",
        "Decreased GI Motility [PE]",
        "Decreased GI Smooth Muscle Tone [PE]",
        "Decreased Glycolysis [PE]",
        "Gastrointestinal Motility Inhibitor [EPC]",
        "Increased Gluconeogenesis [PE]",
        "Increased Glycogenolysis [PE]"
      ]
    }
  ]
}